Medical/Pharmaceuticals
Aussie medtech Ferronova raises another $6 million to advance image-guided cancer surgery
ADELAIDE, Australia, Dec. 17, 2025 /PRNewswire/ -- Australian company Ferronova has raised a further$6 million to progress the commercialisation of a novel nanoparticle image-guided surgery solution seeking to improve identification of cancer cells and reduce the risk of undetected recurrence fol...
2025-12-17 08:30
1765
Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 16, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced amulti-year, global strategi...
2025-12-17 08:04
1493
Jiaying Pharmaceutical: A New Pathway for the Industrialization of Century-Old Hakka Medicine
HONG KONG, Dec. 17, 2025 /PRNewswire/ -- Recently, Meizhou in Guangdong, known as the "World Capital of the Hakka", welcomed a globally watched event, the Seventh World Hakka Entrepreneurs Convention. At this gathering that drew the attention of Hakka entrepreneurs worldwide, Guangdong Jiaying Ph...
2025-12-17 08:00
1254
KPM Analytics Unveils the SmartChem® 800 Series, a Next-Generation Platform for High-Throughput Wet Chemistry
Industry's highest-capacity discrete analyzer delivers true walk-away automation for commercial laboratories WESTBOROUGH, Mass., Dec. 16, 2025 /PRNewswire/ -- Commercial laboratories face mounting pressure to process more samples with fewer staff while maintaining fast turnaround times. When urg...
2025-12-16 22:00
1706
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
* The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters * Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials ...
2025-12-16 21:30
1686
Breakthrough Progress: METiS TechBio Publishes Consecutive Research Findings in Nature Communications and the Journal for ImmunoTherapy of Cancer
BEIJING, Dec. 16, 2025 /PRNewswire/ -- METiS TechBio ("METiS") today announced that two of its oncology pipeline candidates,MTS-105 and MTS-107, have been published in leading international peer-reviewed journals,Nature Communications and theJournal for ImmunoTherapy of Cancer (JITC), representin...
2025-12-16 18:59
1649
Breaking the "Untreatable": Biostar Pharma's UTD1 Achieves First Patient Dosing in U.S. for Pivotal Clinical Trial for Breast Cancer Brain Metastases
SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Cod e: 2563.HK), today announced that the first patient has been dosed for one of its key oversea clinical studies: the U.S. pivotal clinical stud...
2025-12-16 12:55
1792
Allink Biotherapeutics Completes $47M Extension Rounds of Series A to Accelerate Clinical Programs and Novel Platforms Development
* The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters * Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials ...
2025-12-16 08:30
1841
Enginprime Medical Inc Announces First-in-Human Study of Its Leading OpusOne™ pVAD
HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Enginprime Medical Inc ("Enginprime"), an emerging leader in percutaneous ventricular assist device (pVAD) technologies and a Voyagers Capital portfolio company, today announced that its industry leading pVAD, OpusOne™, has entered its first-in-human...
2025-12-16 06:00
1810
HitGen Submits Commitment Letter to Science Based Targets initiative (SBTi)
CHENGDU, China, Dec. 15, 2025 /PRNewswire/ -- HitGen Inc. (hereinafter referred to as "HitGen", SSE: 688222.SH), announced it has officially submitted its commitment letter to the Science Based Targets initiative (SBTi). HitGen has pledged to set near-term science-based targets within the next tw...
2025-12-15 22:30
1999
NYSE Content Advisory: Pre-Market Update + Seven of the Top 10 IPOs in 2025 List on NYSE
NEW YORK, Dec. 15, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on December 15th ...
2025-12-15 22:10
3069
Lunit Announces Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Translational Oncology Research
Collaboration to leverage Lunit SCOPE IO ® and SCOPE universal IHC® (uIHC) digital pathology products in two Daiichi Sankyo oncology research and development programs SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precisi...
2025-12-15 22:00
2274
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE for obesit...
2025-12-15 21:00
2569
Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Leadgene Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development...
2025-12-15 21:00
1513
Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
SHANGHAI and HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New D...
2025-12-15 18:00
4895
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once-daily or potentially once-weekly oral dosing. - ASC50 had strong target engagement after a single oral dose, in...
2025-12-15 17:00
6708
MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
The company is revolutionizing regenerative healthcare through innovation,
clinical alignment, and GMP-grade excellence acrossSoutheast Asia
SAN ANTONIO, Dec. 15, 2025 /PRNewswire/ -- Frost & Sullivan
2025-12-15 17:00
1993
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
* Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient * The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressu...
2025-12-15 15:02
1665
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up ...
2025-12-15 14:06
2504
Manulife and Bupa Sign MoU for Strategic Collaboration in Hong Kong to Create a More Robust, Integrated Healthcare Network Offering Customers Greater Access and Choice
HONG KONG, Dec. 15, 2025 /PRNewswire/ -- Manulife (International) Limited ("Manulife") and Bupa International Limited ("Bupa") are pleased to announce today the signing of a Memorandum of Understanding ("MoU"), intended to establish a strategic collaboration inHong Kong that will provide customer...
2025-12-15 13:45
2770
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 320 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 298 media titles]
2026-02-10 13:31Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Most Read
Agoda Launches Free Global eSIMs for VIP Diamond Members
2026-02-10 14:00
6588
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
6433
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
6336